ReviewFrontiers in medicine2026
Therapeutic potential and research progress of microecological agents in kidney diseases.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with kidney disease often exhibit pathological alterations such as gut dysbiosis, accumulation of uremic toxins, and systemic inflammation. In recent years, microecological agents-represented by pre-biotics, probiotics, and synbiotics-have emerged as a novel strategy targeting the "gut-kidney axis." These agents act through mechanisms including modulation of gut microbiota balance, improvement of intestinal barrier function, reduction of endotoxin levels, and anti-inflammatory as well as antioxidant effects. Our review of the available evidence on microecological agents across various kidney diseases reveals that these interventions can delay the progression of renal function decline in patients with Chronic Kidney Disease (CKD) by restoring gut microbiota balance and reducing the systemic burden of uremic toxins and other harmful metabolites. Concurrently, they help mitigate CKD-related complications, including mineral and bone disorders, cardiovascular and cerebrovascular events, and hyperuricemia. Moreover, microecological agents have demonstrated beneficial effects in attenuating renal injury in acute kidney injury (AKI), reducing the incidence of nephrolithiasis, and exerting a modulatory role in lupus nephritis (LN). However, existing evidence remains unevenly distributed, and conclusions regarding efficacy vary due to differences in the type, dosage, and timing of microecological interventions, thus necessitating a systematic review. This article synthesizes current research on microecological agents across various kidney diseases, systematically evaluates their clinical efficacy and heterogeneity, and discusses future development strategies and translational potential.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.